SEL-201

CAS No. 2095704-43-9

SEL-201( SLV-2436 | SEL201-88 )

Catalog No. M13299 CAS No. 2095704-43-9

SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 97 In Stock
5MG 160 In Stock
10MG 260 In Stock
25MG 496 In Stock
50MG 714 In Stock
100MG 981 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SEL-201
  • Note
    Research use only, not for human use.
  • Brief Description
    SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor.
  • Description
    SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor with IC5010.8/5.4 nM, respectively; displays acceptable kinome selectivity in the broad KINOMEscan (450 distinct kinases); potently suppresses MNK1/2 activity in a panel of KIT-mutant melanoma cell lines, reduces clonogenicity, migration, and lung metastasis of KIT-mutant melanoma cells both in vitro and in vivo.
  • In Vitro
    To confirm the kinome selectivity of SLV-2436 (SEL201), the broad KINOMEscan competitive binding assay is performed at 1 μM, which includes 450 distinct kinases. The observed binding profile for SLV-2436 is significantly concentrated in the CAMK family of kinases that comprises MNK1 and MNK2. SLV-2436-treated KIT-mutant melanoma cells have lower oncogenicity and reduced metastatic ability.
  • In Vivo
    To investigate the pharmacodynamic properties of SLV-2436 (SEL201), 5 consecutive oral doses of 10, 25, and 50 mg/kg are administered to mice every 12 hours (twice-daily schedule). At the 10 mg/kg twice-daily dosage, 4 hours after the fifth administration, a low plasma concentration of 125 ng/mL SLV-2436 is determined. However, dosing at 25 and 50 mg/kg twice daily, equivalent to 50 and 100 mg/kg/d of SLV-2436, yields substantially increased dose-dependent plasma exposure, reaching an average level of 1,299 ng/mL and 2,075 ng/mL, respectively. At the 24-hour time point, SLV-2436 is still detectable in the plasma, with dose-dependent concentrations of 9, 73, and 124 ng/mL in the 10, 25, and 50 mg/kg twice-daily treatment groups. Oral (p.o.) administration of SLV-2436 at the dosage of 50 mg/kg twice daily, that is, 100 mg/kg/d, for 37 days is well tolerated in mice.
  • Synonyms
    SLV-2436 | SEL201-88
  • Pathway
    MAPK/ERK Signaling
  • Target
    MNK
  • Recptor
    MNK1|MNK2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    2095704-43-9
  • Formula Weight
    350.806
  • Molecular Formula
    C19H15ClN4O
  • Purity
    >98% (HPLC)
  • Solubility
    < 1 mg/ml refers to the product slightly soluble or insoluble
  • SMILES
    C1=CC(=CC(=C1)Cl)CN2C=C(C=CC2=O)C3=CC4=C(C=C3)C(=NN4)N
  • Chemical Name
    5-(3-amino-1H-indazol-6-yl)-1-[(3-chlorophenyl)methyl]-1,2-dihydropyridin-2-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhan Y, et al. J Clin Invest. 2017 Nov 1;127(11):4179-4192.
molnova catalog
related products
  • Cercosporamide

    A broad-spectrum natural antifungal compound that acts as a selective and highly potent fungal Pkc1 kinase inhibitor.

  • EB1

    EB1 is a potent and selective MNK kinase inhibitor with inhibitory effects on MNK1 and MNK2 with IC50 values of 0.69 μM and 9.4 μM, respectively.

  • MNK inhibitor 9

    MNK inhibitor 9 is a potent, selective MAPK-interacting kinase (MNK1 and MNK2) inhibitor with IC50 of 3 nM for both, with no activity aginst CDK1/2 (IC50>25 uM).